Pediapharm Announces Grant of Stock Options
23 Januar 2014 - 6:39PM
Marketwired
Pediapharm Announces Grant of Stock Options
MONTREAL, QUEBEC--(Marketwired - Jan 23, 2014) - Pediapharm Inc.
("Pediapharm" or the "Corporation") (TSX-VENTURE:PDP) announces
that its Board of Directors has approved the grant of 3,810,000
stock options to certain directors, officers and employees of the
Corporation, subject to regulatory and TSX Venture Exchange
approval. The options were issued with an exercise price of $0.46
per share and have a term of ten (10) years. In addition, the
options have varied vesting provisions such that they vest either
over three (3) or four (4) years.
About Pediapharm
Pediapharm is the only Canadian specialty pharmaceutical
company, dedicated to serving the needs of the pediatric community.
Its mission is to bring to the Canadian market the latest
innovative pediatric products with the objective to improve the
health and the well-being of children in Canada. Since its debut in
2008, Pediapharm has entered into numerous commercial agreements
with partners from Canada and other countries around the world. The
company's innovative product portfolio includes NYDA®; a
breakthrough treatment for head lice; EpiCeram® a non-steroid
emulsion for eczema; KoolEffect™ which reduces the symptoms of
fever; and VapoLyptus™; a soothing vapour patch of Eucalyptus and
Camphor)
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This press release shall not constitute an offer to sell or
the solicitation of an offer to buy any securities, nor shall there
be any sale of securities in any state in the United States in
which such offer, solicitation or sale would be unlawful. The
securities referred to herein have not been and will not be
registered under the United States Securities Act of 1933, as
amended, and may not be offered or sold in the United States absent
registration or an applicable exemption from registration
requirements.
Sylvain Chretien, President, DirectorPediapharm Inc.514-762-2026
ext. 201sylvain.chretien@pedia-pharm.comRoland Boivin,
CFOPediapharm Inc.514-762-2026 ext.
202roland.boivin@pedia-pharm.com
Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Pediapharm (TSX Venture Börse): 0 Nachrichtenartikel
Weitere Pediapharm News-Artikel